The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis
Use of tocilizumab for COVID-19 since 2021 increased population health while improving health equity, as more patients with lower baseline health were eligible for treatment and received larger relative health gains. Future equitable access to tocilizumab for inpatients with COVID-19 is expected to lead to continued increases in population health and reductions in disparities.
Authors
- Stacey Kowal (ORCID: https://orcid.org/0000-0001-6018-6052)
- Katherine L. Rosettie (ORCID: https://orcid.org/0000-0002-3403-3295)
Institutions
- Genesys (United States) (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s40273-024-01436-1
- Citations
- 5
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- Genentech